News

Luminoah closes $6M Series A round

Charlottesville medical device company Luminoah Inc. has closed a $6 million Series A round it says it will use to complete the development of its mobile feeding tube device that collects data.

The round was led by Charlottesville’s Fry’s Path Capital and included participation from Arlington’s Sands Capital, Charlottesville’s CAV Angels, Virginia Beach’s 757 Angels and Richmond’s Virginia Venture Partners — the equity investment arm of the Virginia Innovation Partnership Corp.

Luminoah, which took top honors at the Light House Labs’ Demo Day competition last month, says its device lets patients to keep a more mobile lifestyle while on a feeding tube. Its data-tracking features also allow remote patient monitoring.

CEO Neal Piper started the company after his young son was diagnosed with cancer and required a constraining feeding tube.

“It’s just a no-brainer to let a kid be active while you pump nutrition into their stomach,” Piper told Richmond Inno last month.

Piper said the goal is to apply for Food and Drug Administration approval in 2024. Luminoah wants to go after the pediatric home health care market initially, but also seeks to move into senior and rehabilitation markets. The company says the enteral feeding technology market is worth about $12 billion and that half-a-million children could benefit from its product.

Learn more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business